SPDR MSCI USA StrategicFactors ETF Sees Significant Withdrawal of Funds
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Dec 04 2025
0mins
Should l Buy VRTX?
Source: NASDAQ.COM
QUS Share Price Analysis: QUS's share price is currently at $173.76, with a 52-week low of $137.58 and a high of $174.10, indicating a stable position near its high point.
Understanding ETFs: Exchange-traded funds (ETFs) function like stocks, where investors buy and sell "units" that can be created or destroyed based on demand, impacting the underlying assets.
Monitoring ETF Flows: Weekly monitoring of shares outstanding helps identify ETFs with significant inflows (new units created) or outflows (units destroyed), which can affect the individual components of the ETFs.
Disclaimer on Views: The opinions expressed in the article are those of the author and do not necessarily represent the views of Nasdaq, Inc.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy VRTX?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on VRTX
Wall Street analysts forecast VRTX stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for VRTX is 515.88 USD with a low forecast of 414.00 USD and a high forecast of 604.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
22 Analyst Rating
17 Buy
5 Hold
0 Sell
Strong Buy
Current: 461.240
Low
414.00
Averages
515.88
High
604.00
Current: 461.240
Low
414.00
Averages
515.88
High
604.00
About VRTX
Vertex Pharmaceuticals Incorporated is a global biotechnology company that invests in scientific innovation to create transformative medicines for people with serious diseases, with a focus on specialty markets. It has seven approved medicines: five that treat the underlying cause of cystic fibrosis (CF), one that treats severe sickle cell disease (SCD) and transfusion dependent beta thalassemia (TDT), and one that treats moderate-to-severe acute pain. Its pipeline includes clinical-stage programs in CF, SCD, beta thalassemia, acute and peripheral neuropathic pain, APOL1-mediated kidney disease, IgA nephropathy and other autoimmune renal diseases and cytopenias, type 1 diabetes, myotonic dystrophy type 1, and autosomal dominant polycystic kidney disease. Its marketed medicines are TRIKAFTA/KAFTRIO (elexacaftor/tezacaftor/ivacaftor and ivacaftor), SYMDEKO/SYMKEVI (elexacaftor/tezacaftor/ivacaftor and ivacaftor), ORKAMBI (lumacaftor/ivacaftor), and KALYDECO (ivacaftor).
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Vertex Pharmaceuticals Set to Release Q4 Earnings on February 12
- Earnings Announcement Schedule: Vertex Pharmaceuticals is set to announce its Q4 2023 earnings on February 12 after market close, with consensus EPS estimated at $5.15, reflecting a 29.4% year-over-year increase, and revenue expected to reach $3.17 billion, up 8.9% year-over-year.
- Historical Performance Review: Over the past two years, Vertex has exceeded EPS estimates 63% of the time and revenue estimates 75% of the time, indicating its strong profitability and market performance.
- Expectation Revision Dynamics: In the last three months, EPS estimates have seen five upward revisions and five downward adjustments, while revenue estimates have experienced seven upward revisions and six downward changes, reflecting analyst divergence and market uncertainty regarding the company's future performance.
- Industry Focus: During the upcoming earnings week, Vertex will be among the companies drawing attention alongside notable firms like Johnson & Johnson, Moderna, and Bristol Myers, potentially influencing investor sentiment towards the broader biopharmaceutical sector.
See More
Multiple Companies Shine in After-Hours Trading
- Applied Materials Earnings Beat: California-based semiconductor equipment company Applied Materials reported adjusted earnings of $2.38 per share and revenue of $7.01 billion, both exceeding analyst expectations, leading to an 11% stock price increase that reflects strong market demand and profitability.
- Coinbase Trading Volume Surge: Coinbase announced a total trading volume of $5.2 trillion in 2025, up 156% year-over-year, and despite missing fourth-quarter revenue expectations, its stock rose nearly 2%, indicating robust performance in the crypto market.
- Rivian Delivery Forecast Upgrade: Electric truck manufacturer Rivian expects vehicle deliveries for 2026 to range from 62,000 to 67,000 units, representing a 47% to 59% increase compared to 2025, resulting in a 14% stock price surge that reflects market confidence in its growth potential.
- Airbnb's Upbeat Guidance: Airbnb reported fourth-quarter earnings of $0.56 per share on $2.78 billion in revenue, falling short of analyst expectations, yet the company anticipates full-year revenue growth of at least low double digits, leading to a stock increase of about 2%, showcasing market confidence in its future growth.
See More
Vertex Pharmaceuticals' 2026 Revenue Guidance Meets Consensus Expectations
- Guidance Meets Expectations: Vertex Pharmaceuticals projects 2026 revenue between $12.95 billion and $13.1 billion, aligning with the consensus estimate of $13 billion, indicating confidence in future growth.
- Significant Contribution from New Therapies: The company anticipates at least $500 million in revenue from non-cystic fibrosis treatments in 2026, primarily driven by the launch of gene therapy Casgevy and the first-in-class non-opioid painkiller Journavx, marking a strategic expansion into new therapeutic areas.
- Q4 Financial Performance: Although the Q4 non-GAAP EPS of $5.03 missed expectations by $0.12, overall revenue increased by 9.6% year-over-year to $3.19 billion, reflecting the company's stable performance in the market.
- Increased Cash Reserves: Vertex ended 2025 with approximately $6.6 billion in cash, cash equivalents, and marketable securities, up from $6.1 billion at the end of 2024, enhancing the company's financial flexibility for future investments.
See More
Vertex Pharmaceuticals Provides FY 2026 Financial Guidance
- Earnings Performance: Vertex Pharmaceuticals reported a Q4 non-GAAP EPS of $5.03, missing estimates by $0.12, while revenue reached $3.19 billion, reflecting a 9.6% year-over-year growth and beating market expectations by $20 million, indicating stability in revenue growth.
- FY 2026 Revenue Guidance: The company projects total revenue for FY 2026 to be between $12.95 billion and $13.1 billion, slightly below the consensus estimate of $13 billion, reflecting market caution regarding its future growth prospects.
- R&D and Expense Guidance: Vertex anticipates combined GAAP R&D, AIP R&D, and SG&A expenses to range from $6.3 billion to $6.45 billion, while non-GAAP expenses are expected to be between $5.65 billion and $5.75 billion, demonstrating the company's efforts in cost control.
- Tax Rate Expectations: The company expects a non-GAAP effective tax rate between 19.5% and 20.5%, which will impact future net income and reflects the company's commitment to financial transparency.
See More
Tech Earnings Show Diverging Trends Amid Market Volatility
- Cisco's Revenue Decline: Cisco (CSCO) fell over 8% in pre-market trading due to a 4% drop in security segment revenue and tightening operating cash flow, although the CFO indicated plans to enhance profitability through financial discipline, highlighting the challenges and strategic responses the company faces.
- Paycom's Slower Growth: Paycom (PAYC) saw its stock drop more than 9% in pre-market trading after reporting a 10.2% year-over-year revenue gain but providing a slower growth outlook, which may dampen investor confidence and affect market performance.
- Cognex's Strong Surge: Cognex (CGNX) surged nearly 25% in pre-market trading, with the CEO attributing the impressive financial results to advancements in AI-enabled industrial machine vision, reflecting strong market demand and recognition for AI technologies.
- Real Estate Stocks Hit by AI Concerns: Real estate service stocks CBRE and JLL closed 12% lower yesterday amid growing concerns about AI's disruptive potential in the sector, indicating that their high-fee, labor-intensive operating models may face profitability pressures.
See More
Stock Movers: Cisco, AppLovin, Micron, Fastly, Equinix, Rollins, Novocure, and Others
- Stock Market Trends: Stock futures were rising on Thursday as investors reacted to recent economic data.
- Economic Data Impact: The rise in stock futures comes in the wake of a delayed U.S. monthly jobs report and other economic indicators.
See More
Vertex Pharmaceuticals Set to Release Q4 Earnings on February 12
- Earnings Announcement Schedule: Vertex Pharmaceuticals is set to announce its Q4 2023 earnings on February 12 after market close, with consensus EPS estimated at $5.15, reflecting a 29.4% year-over-year increase, and revenue expected to reach $3.17 billion, up 8.9% year-over-year.
- Historical Performance Review: Over the past two years, Vertex has exceeded EPS estimates 63% of the time and revenue estimates 75% of the time, indicating its strong profitability and market performance.
- Expectation Revision Dynamics: In the last three months, EPS estimates have seen five upward revisions and five downward adjustments, while revenue estimates have experienced seven upward revisions and six downward changes, reflecting analyst divergence and market uncertainty regarding the company's future performance.
- Industry Focus: During the upcoming earnings week, Vertex will be among the companies drawing attention alongside notable firms like Johnson & Johnson, Moderna, and Bristol Myers, potentially influencing investor sentiment towards the broader biopharmaceutical sector.
See More
Multiple Companies Shine in After-Hours Trading
- Applied Materials Earnings Beat: California-based semiconductor equipment company Applied Materials reported adjusted earnings of $2.38 per share and revenue of $7.01 billion, both exceeding analyst expectations, leading to an 11% stock price increase that reflects strong market demand and profitability.
- Coinbase Trading Volume Surge: Coinbase announced a total trading volume of $5.2 trillion in 2025, up 156% year-over-year, and despite missing fourth-quarter revenue expectations, its stock rose nearly 2%, indicating robust performance in the crypto market.
- Rivian Delivery Forecast Upgrade: Electric truck manufacturer Rivian expects vehicle deliveries for 2026 to range from 62,000 to 67,000 units, representing a 47% to 59% increase compared to 2025, resulting in a 14% stock price surge that reflects market confidence in its growth potential.
- Airbnb's Upbeat Guidance: Airbnb reported fourth-quarter earnings of $0.56 per share on $2.78 billion in revenue, falling short of analyst expectations, yet the company anticipates full-year revenue growth of at least low double digits, leading to a stock increase of about 2%, showcasing market confidence in its future growth.
See More
Vertex Pharmaceuticals' 2026 Revenue Guidance Meets Consensus Expectations
- Guidance Meets Expectations: Vertex Pharmaceuticals projects 2026 revenue between $12.95 billion and $13.1 billion, aligning with the consensus estimate of $13 billion, indicating confidence in future growth.
- Significant Contribution from New Therapies: The company anticipates at least $500 million in revenue from non-cystic fibrosis treatments in 2026, primarily driven by the launch of gene therapy Casgevy and the first-in-class non-opioid painkiller Journavx, marking a strategic expansion into new therapeutic areas.
- Q4 Financial Performance: Although the Q4 non-GAAP EPS of $5.03 missed expectations by $0.12, overall revenue increased by 9.6% year-over-year to $3.19 billion, reflecting the company's stable performance in the market.
- Increased Cash Reserves: Vertex ended 2025 with approximately $6.6 billion in cash, cash equivalents, and marketable securities, up from $6.1 billion at the end of 2024, enhancing the company's financial flexibility for future investments.
See More
Vertex Pharmaceuticals Provides FY 2026 Financial Guidance
- Earnings Performance: Vertex Pharmaceuticals reported a Q4 non-GAAP EPS of $5.03, missing estimates by $0.12, while revenue reached $3.19 billion, reflecting a 9.6% year-over-year growth and beating market expectations by $20 million, indicating stability in revenue growth.
- FY 2026 Revenue Guidance: The company projects total revenue for FY 2026 to be between $12.95 billion and $13.1 billion, slightly below the consensus estimate of $13 billion, reflecting market caution regarding its future growth prospects.
- R&D and Expense Guidance: Vertex anticipates combined GAAP R&D, AIP R&D, and SG&A expenses to range from $6.3 billion to $6.45 billion, while non-GAAP expenses are expected to be between $5.65 billion and $5.75 billion, demonstrating the company's efforts in cost control.
- Tax Rate Expectations: The company expects a non-GAAP effective tax rate between 19.5% and 20.5%, which will impact future net income and reflects the company's commitment to financial transparency.
See More
Tech Earnings Show Diverging Trends Amid Market Volatility
- Cisco's Revenue Decline: Cisco (CSCO) fell over 8% in pre-market trading due to a 4% drop in security segment revenue and tightening operating cash flow, although the CFO indicated plans to enhance profitability through financial discipline, highlighting the challenges and strategic responses the company faces.
- Paycom's Slower Growth: Paycom (PAYC) saw its stock drop more than 9% in pre-market trading after reporting a 10.2% year-over-year revenue gain but providing a slower growth outlook, which may dampen investor confidence and affect market performance.
- Cognex's Strong Surge: Cognex (CGNX) surged nearly 25% in pre-market trading, with the CEO attributing the impressive financial results to advancements in AI-enabled industrial machine vision, reflecting strong market demand and recognition for AI technologies.
- Real Estate Stocks Hit by AI Concerns: Real estate service stocks CBRE and JLL closed 12% lower yesterday amid growing concerns about AI's disruptive potential in the sector, indicating that their high-fee, labor-intensive operating models may face profitability pressures.
See More
Stock Movers: Cisco, AppLovin, Micron, Fastly, Equinix, Rollins, Novocure, and Others
- Stock Market Trends: Stock futures were rising on Thursday as investors reacted to recent economic data.
- Economic Data Impact: The rise in stock futures comes in the wake of a delayed U.S. monthly jobs report and other economic indicators.
See More
